Pharmacogenetics in psychiatry: Translating research into clinical practice

Molecular Psychiatry

Volumn 17, Issue 8, 2012, Pages 760-769

  Malhotra, A K ^a,b   Zhang, J P ^a,b   Lencz, T ^a,b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

antidepressants; antipsychotics; gene; pharmacogenetics; treatment

Indexed keywords

ANTIDEPRESSANT AGENT; CLOZAPINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; ESCITALOPRAM; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

CLINICAL PRACTICE; DRUG EFFICACY; GENETIC ASSOCIATION; HUMAN; META ANALYSIS (TOPIC); METHODOLOGY; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; PSYCHIATRY; REVIEW; SCHIZOPHRENIA; TRANSLATIONAL RESEARCH;

BIOMARKERS, PHARMACOLOGICAL; GENETIC TESTING; HUMANS; PHARMACOGENETICS; PSYCHOTROPIC DRUGS; RESEARCH DESIGN; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84864342355     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2011.146     Document Type: Review

References (60)

1. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of Schizophrenia: a review of last decade of research. Mol Psychiatry 2007; 12: 707-747. (Pubitemid 47172693)
2. Zhang JP, Malhotra AK. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol 2011; 7: 9-37.
3. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010; 15: 473-500.
4. Sturgess JE, George TP, Kennedy JL, Heinz A, Muller DJ. Pharmacogenetics of alcohol, nicotine and drug addiction treatments. Addict Biol 2011; 16: 357-376.
5. Fleeman N, Dundar Y, Dickson R, Jorgensen A, Pushpakom S, McLeod C et al. Cytochrome P450 testing for prescribing antipsychotics in adults with Schizophrenia: systematic review and meta-analyses. Pharmacogenomics J 2011; 11: 1-14.
6. Taylor MJ, Sen S, Bhagwagar Z. Antidepressant response and the serotonin transporter gene-Linked polymorphic region. Biol Psychiatry 2010; 68: 536-543.
7. McCarthy MJ, Leckband SG, Kelsoe Jr. Pharmacogenetics of lithium response in bipolar disorder. Pharmacogenomics 2010; 11: 1439-1465.
8. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1081-1090. (Pubitemid 37464954)
9. Zhang JP, Lencz T, Malhotra AK. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry 2010; 167: 763-772.
10. Serretti A, Kato M, De Ronchi D, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007; 12: 247-257. (Pubitemid 46328503)
11. Mizutani T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev 2003; 35: 99-106. (Pubitemid 37048293)
12. Ulrich S, Lauter J. Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression. Clin Pharmacokinet 2002; 41: 853-876.
13. Conley RR. Optimizing treatment with clozapine. J Clin Psychiatry 1998; 59(Suppl 3): 44-48. (Pubitemid 28196370)
14. de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006; 47: 75-85. (Pubitemid 43017126)
15. Cichon S, Craddock N, Daly M, Faraone SV, Gejman PV, Kelsoe J et al. Genomewide association studies: history, rationale, and prospects for psychiatric disorders. Am J Psychiatry 2009; 166: 540-556.
16. Uher R, Perroud N, Ng MY, Hauser J, Henigsberg N, Maier Wet al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 2010; 167: 555-564.
17. Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, Jenkins GD et al. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 2011; 67: 133-138.
18. Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 2009; 66: 966-975.
19. Perlis RH, Smoller JW, Ferreira MA, McQuillin A, Bass N, Lawrence J et al. A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. Am J Psychiatry 2009; 166: 718-725.
20. Aberg K, Adkins DE, Bukszar J, Webb BT, Caroff SN, Miller DD et al. Genomewide association study of movement-related adverse antipsychotic effects. Biol Psychiatry 2010; 67: 279-282.
21. Adkins DE, Aberg K, McClay JL, Bukszár J, Zhao Z, Jia P et al. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol Psychiatry 2011; 16: 321-332.
22. Alkelai A, Greenbaum L, Rigbi A, Kanyas K, Lerer B. Genomewide association study of antipsychotic-induced parkinsonism severity among Schizophrenia patients. Psychopharmacology (Berl) 2009; 206: 491-499.
23. McClay JL, Adkins DE, Aberg K, Stroup S, Perkins DO, Vladimirov VI et al. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol Psychiatry 2011; 16: 76-85.
24. McGuire AL, Evans BJ, Caulfield T, Burke W. Science and regulation. Regulating direct-to-consumer personal genome testing. Science (New York, NY) 2010; 330: 181-182.
25. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I et al. CYP2D6 AND CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104: 173-192. (Pubitemid 32762271)
26. de Leon J. Pharmacogenomics: the promise of personalized medicine for CNS disorders. Neuropsychopharmacology 2009; 34: 159-172.
27. Malhotra AK, Lencz T, Correll CU, Kane JM. Genomics and the future of pharmacotherapy in psychiatry. Int Rev Psychiatry (Abingdon, England) 2007; 19: 523-530. (Pubitemid 47493739)
28. Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode Schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003; 28: 995-1003.
29. Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B et al. Predictors of treatment response from a first episode of Schizophrenia or schizoaffective disorder. Am J Psychiatry 1999; 156: 544-549. (Pubitemid 29162974)
30. Perkins DO, Wyatt RJ, Bartko JJ. Penny-wise and pound-foolish: the impact of measurement error on sample size requirements in clinical trials. Biol Psychiatry 2000; 47: 762-766. (Pubitemid 30201674)
31. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A et al. HLA-B*5701 genotype is a major determinant of druginduced liver injury due to flucloxacillin. Nat Genet 2009; 41: 816-819.
32. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-579.
33. Hung SI, Chung WH, Liu ZS, Chen CH, Hsih MS, Hui RC et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 2010; 11: 349-356.
34. Kazeem GR, Cox C, Aponte J, Messenheimer J, Brazell C, Nelsen AC et al. High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients. Pharmacogenet Genomics 2009; 19: 661-665.
35. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796.
36. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic Schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163: 600-610. (Pubitemid 44464569)
37. Kelly DL, Dixon LB, Kreyenbuhl JA, Medoff D, Lehman AF, Love RC et al. Clozapine utilization and outcomes by race in a public mental health system: 1994-2000. J Clin Psychiatry 2006; 67: 1404-1411. (Pubitemid 44583388)
38. Athanasiou MC, Dettling M, Cascorbi I, Mosyagin I, Salisbury BA, Pierz KA et al. Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry 2011; 72: 458-463.
39. Parsons B, Allison DB, Loebel A, Williams K, Giller E, Romano S et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res 2009; 110: 103-110.
40. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Effectiveness of antipsychotic drugs in patients with chronic Schizophrenia. N Engl J Med 2005; 353: 1209-1223. (Pubitemid 41345943)
41. Pandina GJ, Aman MG, Findling RL. Risperidone in the management of disruptive behavior disorders. J Child Adolesc Psychopharmacol 2006; 16: 379-392. (Pubitemid 44681459)
42. Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L et al. Double-blind comparison of first-and second-generation antipsychotics in early-onset Schizophrenia and schizo-affective disorder: findings from the treatment of early-onset Schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008; 165: 1420-1431.
43. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302: 1765-1773.
44. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002; 359: 2086-2087. (Pubitemid 34680975)
45. Templeman LA, Reynolds GP, Arranz B, San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2005; 15: 195-200. (Pubitemid 40569890)
46. Sicard MN, Zai CC, Tiwari AK, Souza RP, Meltzer HY, Lieberman JA et al. Polymorphisms of the HTR2C gene and antipsychoticinduced weight gain: an update and meta-analysis. Pharmacogenomics 2010; 11: 1561-1571.
47. Lencz T, Robinson DG, Napolitano B, Sevy S, Kane JM, Goldman D et al. DRD2 promoter region variation predicts antipsychoticinduced weight gain in first episode Schizophrenia. Pharmacogenet Genomics 2010; 20: 569-572.
48. Julius RJ, Novitsky Jr MA, Dubin WR. Medication adherence: a review of the literature and implications for clinical practice. J Psychiatr Pract 2009; 15: 34-44.
49. Zhang JP, Lencz T, Malhotra AK. Enhancing power in pharmacogenetic studies: maximizing adherence and meta-analytic strategies. Symposium Presented at the Society of Biological Psychiatry Annual Meeting. San Francisco, CA, 13th May 2011.
50. Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009; 70(Suppl 4): 1-46; quiz 47-48.
51. Sullivan PF. The psychiatric GWAS consortium: big science comes to psychiatry. Neuron 2010; 68: 182-186.
52. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ et al. Finding the missing heritability of complex diseases. Nature 2009; 461: 747-753.
53. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-1698. (Pubitemid 34289221)
54. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010; 304: 1821-1830.
55. De Luca V, Mueller DJ, de Bartolomeis A, Kennedy JL. Association of the HTR2C gene and antipsychotic induced weight gain: a metaanalysis. Int J Neuropsychopharmacol 2007; 10: 697-704. (Pubitemid 47517523)
56. Simon GE, Perlis RH. Personalized medicine for depression: can we match patients with treatments? Am J Psychiatry 2010; 167: 1445-1455.
57. Johnson BA, Ait-Daoud N, Seneviratne C, Roache JD, Javors MA, Wang XQ et al. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry 2011; 168: 265-275.
58. Kirchheiner J, Fuhr U, Brockmoller J. Pharmacogenetics-based therapeutic recommendations-ready for clinical practice? Nat Rev Drug Discov 2005; 4: 639-647. (Pubitemid 41149757)
59. Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008; 299: 185-193.
60. Lenzini PA, Grice GR, Milligan PE, Dowd MB, Subherwal S, Deych E et al. Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. J Thromb Haemost 2008; 6: 1655-1662.